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Reinforcing Effects Of Compounds Lacking Intrinsic Efficacy
At a1 Subunit-Containing GABAA Receptor Subtypes in
Midazolam- But Not Cocaine-Experienced Rhesus Monkeys
Nina M Shinday1,2, Eileen K Sawyer1, Bradford D Fischer1, Donna M Platt1, Stephanie C Licata3,
John R Atack4, Gerard R Dawson5, David S Reynolds6 and James K Rowlett*,1,2
1

Department of Psychiatry, Division of Neuroscience, New England Primate Research Center, Beth Israel Deaconess Medical Center and
Harvard Medical School, MA, USA; 2Neuroscience and Behavior Program, University of Massachusetts-Amherst, MA, USA; 3Behavioral
Psychopharmacology Research Laboratory, Imaging Center, McLean Hospital-Harvard Medical School, MA, USA; 4Translational Drug Discovery
Group, School of Life Sciences, University of Sussex, Brighton, UK; 5Department of Psychiatry, P1Vital, University of Oxford, Warneford Hospital,
Headington, Oxford, UK; 6Discovery Biology, Pfizer Global Research and Development, Sandwich, Kent, UK

Benzodiazepines are prescribed widely but their utility is limited by unwanted side effects, including abuse potential. The mechanisms
underlying the abuse-related effects of benzodiazepines are not well understood, although a1 subunit-containing GABAA receptors have
been proposed to have a critical role. Here, we examine the reinforcing effects of several compounds that vary with respect to intrinsic
efficacy at a2, a3, and a5 subunit-containing GABAA receptors but lack efficacy at a1 subunit-containing GABAA receptors (‘a1-sparing
compounds’): MRK-623 (functional selectivity for a2/a3 subunit-containing receptors), TPA023B (functional selectivity for a2/a3/a5
subunit-containing receptors), and TP003 (functional selectivity for a3 subunit-containing receptors). The reinforcing effects of the
a1-sparing compounds were compared with those of the non-selective benzodiazepine receptor partial agonist MRK-696, and
non-selective benzodiazepine receptor full agonists, midazolam and lorazepam, in rhesus monkeys trained to self-administer midazolam
or cocaine, under a progressive-ratio schedule of intravenous (i.v.) drug injection. The a1-sparing compounds were self-administered
significantly above vehicle levels in monkeys maintained under a midazolam baseline, but not under a cocaine baseline over the dose
ranges tested. Importantly, TP003 had significant reinforcing effects, albeit at lower levels of self-administration than non-selective
benzodiazepine receptor agonists. Together, these results suggest that a1 subunit-containing GABAA receptors may have a role in the
reinforcing effects of benzodiazepine-type compounds in monkeys with a history of stimulant self-administration, whereas a3
subunit-containing GABAA receptors may be important mediators of the reinforcing effects of benzodiazepine-type compounds in
animals with a history of sedative-anxiolytic/benzodiazepine self-administration.
Neuropsychopharmacology (2013) 38, 1006–1014; doi:10.1038/npp.2012.265; published online 16 January 2013
Keywords: benzodiazepine; GABAA receptor; alpha subunit; self-administration; drug history; rhesus monkey (Macaca mulatta)

INTRODUCTION
Although significant new information has accrued in recent
years on mechanisms of action underlying the therapeutic
effects of benzodiazepines, the precise mechanism(s)
of action underlying the addictive effects of these
widely-abused drugs remains elusive. Benzodiazepines
potentiate the effects of the neurotransmitter g-aminobutyric acid (GABA) via positive allosteric modulation at the
*Correspondence: Dr JK Rowlett, Department of Psychiatry, Division
of Neuroscience, New England Primate Research Center, Beth Israel
Deaconess Medical Center and Harvard Medical School, Pine Hill Rd,
Box 9102, Southborough, MA 01772, USA. Tel: +508 624 8036,
Fax: +508 624 8197, E-mail: james_rowlett@hms.harvard.edu
Received 30 August 2012; revised 3 December 2012; accepted 5
December 2012; accepted article preview online 27 December 2012

g-aminobutyric acid type A (GABAA) receptor. GABAA
receptors are heteropentameric chloride ion channels
assembled in a typical stoichiometry of 2 a, 2 b, and 1 g
subunits; conventional benzodiazepines bind to GABAA
receptors containing a1, a2, a3, or a5 subunits (a1GABAA,
a2GABAA, a3GABAA, or a5GABAA receptors, respectively;
Rudolph and Knoflach, 2011; Tan et al, 2011). Previous
studies have shown localization of a1GABAA receptors on
inhibitory interneurons that synapse with DA neurons in
the ventral tegmental area (VTA; Heikkinen et al, 2009; Tan
et al, 2010) while a3GABAA receptors are expressed at lower
levels on the DA neurons themselves (Fritschy and Mohler,
1995; Ciccarelli et al, 2012). Benzodiazepines decrease firing
of these interneurons via a1GABAA receptors, resulting in a
net effect of decreased activity, ie, ‘disinhibition’, of DA
neurons. The ultimate outcome would be an increase in DA
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release in the nucleus accumbens (NAc; Tan et al, 2010;
2011), although this effect has yet to be established for
benzodiazepines (eg Finlay et al, 1992; Murai et al, 1994). If
this hypothesis is correct, then compounds lacking activity
at a1GABAA receptors (ie, ‘a1-sparing compounds’) should
lack abuse potential (Tan et al, 2010; 2011).
Currently, there is mixed evidence for the idea that
a1-sparing compounds lack abuse potential. Supporting this,
the a1-sparing compound, TPA023, was not self-administered
by baboons up to doses that completely occupied benzodiazepine binding sites as measured via positron emission
tomography (Ator et al, 2010). Moreover, mice with point
mutations rendering the a1GABAA receptor insensitive to
benzodiazepines did not show a preference for oral midazolam vs sucrose solutions, in contrast to wild-type mice
(Tan et al, 2010). We have shown, however, that the a1sparing compound, L-838,417, was reliably self-administered
by rhesus monkeys (Rowlett et al, 2005), a finding clearly
inconsistent with the hypothesis that a1GABAA receptors
mediate the reinforcing effects of benzodiazepines.
The reasons for the discrepancies in the results with
TPA023 and L-838,417 are unclear. A possibility is the
differences in the pharmacological profiles of the two
compounds: TPA023 has notably lower intrinsic efficacy
in vitro (measured via Cl- conductance in cloned human
receptor subtypes) than L-838,417, with the highest efficacy
for TPA023 at a3GABAA receptors whereas L-838 417 is
equi-effective at a2GABAA, a3 GABAA, and a5GABAA
receptors, raising the possibility that differences in levels
of intrinsic efficacy could be key factors mediating selfadministration (for reviews, see Licata and Rowlett, 2008;
Atack, 2011). Moreover, TPA023 likely has a relatively long
duration of action (Atack et al, 2006, 2010; Ator et al, 2010)
while that of L-838 417 is shorter (Rowlett et al, 2005; Licata
et al, 2010; J.R. Atack, unpublished data). Benzodiazepines
with relatively long durations of action typically are less
robustly self-administered compared with short-acting
drugs (Griffiths and Weerts, 1997; Platt and Rowlett, 2012).
To address the extent to which our findings
with L-838,417 generalize to compounds with different
pharmacodynamic and pharmacokinetic characteristics, the

present study evaluated the reinforcing effects of novel
a1-sparing compounds from different chemical classes
with different relative durations of action and functional
selectivity profiles. These compounds included a longacting imidazotriazine referred to as TPA023B, the relatively
short-acting imidazopyrimidine MRK-623, and the relatively long-acting fluoroimidazopyridine TP003. Each of the
novel compounds has a non-selective binding affinity
profile (see Table 1), but demonstrates higher intrinsic
efficacy at one or more receptor subtypes compared with
the a1GABAA receptor (ie, they are functionally selective
in vitro; see Figure 1).
Although there are several differences between the studies
of Ator et al (2010) and Rowlett et al (2005), one potentially
important difference is training/maintenance drug (cocaine
vs methohexital). Drug history, including the type of drug
used for self-administration training, has been shown to be
a major determinant of the reinforcing effects of benzodiazepines (Nelson et al, 1983; Bergman and Johanson,
1985; Falk and Tang, 1989). Therefore, we examined
self-administration of the different a1-sparing compounds
described above in monkeys trained to self-administer
either a benzodiazepine agonist (midazolam), or the
psychomotor stimulant cocaine, in order to match the
training conditions of Ator et al (2010). For comparisons
across the two baseline conditions, we also included tests
with non-selective benzodiazepine full agonists (midazolam,
lorazepam) and a non-selective benzodiazepine partial
agonist (MRK-696, see Table 1; Figure 1).

MATERIALS AND METHODS
Subjects, Surgery, and Design
Eight adult rhesus monkeys (Macaca mulatta; four males,
four females) were housed in a colony room with a
12 h light/dark cycle, had unrestricted access to water, and
were fed Harlan Teklad monkey diet, supplemented by fresh
fruit. Animals were maintained in accordance with the
guidelines of the Committee on Animals of the Harvard
Medical School and the Guide for Care and Use of

Table 1 Potencies for Novel Compounds at GABAA Receptors (Affinities) and in Self-Administration (Dose Engendering Half-Maximal
Effects, ED50) Under Midazolam Baseline Conditions
GABAA subtype (a x b3c2)
a1

a2

a3

a5
Self-administration
ED50(mean mg/kg/injection± SEM)b

Ki (nM)a

Compound
MRK-696

0.14

0.22

0.11

0.14

TP003

0.32

0.54

0.50

0.26

TPA023B

0.73

2.00

1.80

1.10

MRK-623

0.85

3.70

4.00

0.53

a

0.0011±0.0009
0.49±0.21
0.0032±0.001
0.09±0.01

3

Ki values determined from radioligand binding assays with [ H]flumazenil in human recombinant GABAA receptors containing b3 and g2 subunits, combined with a1,
a2, a3, or a5 subunits (adapted from Atack, 2011).
b
ED50 values determined for monkeys responding under a progressive-ratio schedule of i.v. midazolam injection (‘midazolam baseline’ group). Data are from N ¼ 4
rhesus monkeys.
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Figure 1 Intrinsic efficacy profiles of novel compounds with functional selectivity for GABAA receptor subtypes. Intrinsic efficacy values were determined
in human recombinant GABAA receptors containing b3 and g2 subunits, combined with a1, a2, a3, or a5 subunits, using whole-cell patch-clamp
electrophysiology. Values are expressed relative to the efficacy measured at each subtype using the nonselective high efficacy benzodiazepine agonist
chlordiazepoxide. Graphs are adapted from (Atack 2010, 2011).

Laboratory Animals (eighth edition, 2011). Research protocols were approved by the Harvard Medical School
Institutional Animal Care and Use Committee.
Monkeys were prepared with chronic indwelling venous
catheters (polyvinyl chloride, i.d.: 0.64 mm; o.d.: 1.35 mm)
following the general surgical procedures described
by (Platt et al, 2011). Monkeys were anesthetized with
10–20 mg/kg i.m. of ketamine for preparation for the
procedure. Throughout surgery, anesthesia was maintained
by an isofluorane/oxygen mixture. Under aseptic conditions, a catheter was implanted in the femoral, brachial, or
jugular vein and passed to the level of the right atrium.
The distal end of the catheter was passed subcutaneously
and exited in the mid-scapular region. The external end of
the catheter was fed through a fitted jacket and tether
system (Lomir Biomedical, Toronto, Canada) and attached
to a fluid swivel mounted to the animal’s cage. The catheters
were flushed daily with heparinized saline (150–200 U/ml).
Two groups of monkeys (each consisting of two males
and two females) were trained to self-administer either the
benzodiazepine agonist midazolam (0.03 mg/kg/injection,
referred to as ‘midazolam baseline’ group) or cocaine
(0.03 mg/kg/injection, referred to as ‘cocaine baseline’
group) under a progressive-ratio (PR) schedule of i.v. drug
injection (Rowlett et al, 2005; Rowlett and Lelas, 2007).
Previously, the monkeys in the midazolam baseline group
had received single-day tests with other benzodiazepines
(clonazepam, diazepam, alprazolam, triazolam) over an
approximately 6-month period (unpublished). The monkeys in the cocaine baseline group had received single-day
tests with cocaine and/or opioid agonists (alfentanil
and nalbuphine) over the course of approximately a year
(Rowlett et al, 2002). Both groups of monkeys had
Neuropsychopharmacology

received numerous injections of ketamine as part of routine
clinical care.

Self-Administration Training and Testing
Each monkey’s cage was fitted with a custom-made panel
(MetalSmiths) containing stimulus lights and levers
(Med Associates). At the beginning of a session, a set of
two white stimulus lights above a response lever was
illuminated. Upon completion of a response requirement,
the white lights were extinguished and a set of two red
stimulus lights were illuminated for 1 s, coinciding with
a 1-s infusion. Each trial ended with either an injection or
the expiration of a 30-min limited hold. Trials were
separated by a 30-min timeout period, during which all
lights were extinguished and responding had no programmed consequences.
Experimental sessions consisted of five components made
up of four trials each. The response requirement remained
constant for each of the four trials within a component, and
doubled during each successive component. The session
ended when a monkey self-administered a maximum of
20 injections or when the response requirement was not
completed for two consecutive trials. The PR schedule
consisted of the sequence of response requirements 40, 80,
160, 320, and 640 responses per injection. Once performance was stable under these conditions (no increasing or
decreasing trend in the number of injections/session for
three consecutive sessions), drug (midazolam or cocaine,
depending on the baseline condition) or saline was available
on alternating days. Test sessions (T) with experimental
compounds were added to the alternating sequence of drug
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(D) and saline (S) sessions according to the following
sequence: DTSDTSTDST, etc.

Functional Selectivity Profiles and Drug/Compound
Information
Three novel a1-sparing compounds were evaluated:
TPA023B, MRK-623, and TP003 (see Table 1 and Figure 1
for details). TPA023B is functionally selective for a2GABAA,
a3GABAA, and a5GABAA receptors, similar to the
previously-tested L-838,417, whereas MRK-623 exhibits
functional selectivity at a2GABAA and a3GABAA receptors
compared with a1GABAA and a5GABAA receptors.
In contrast, TP003 has appreciable intrinsic efficacy for
a3GABAA receptors, but essentially no measurable intrinsic
efficacy at a1GABAA, a2GABAA, and a5GABAA receptors.
Therefore, in addition to providing information about the
necessity of action at a1GABAA receptors for self-administration, these studies provided key information on the role
of a2GABAA, a3GABAA, and a5GABAA receptors in the
reinforcing effects of benzodiazepine-type drugs. Comparisons were made with conventional benzodiazepines
(midazolam, lorazepam) as well as with a non-selective
partial agonist, MRK-696.
All drugs were administered intravenously. The base forms
of midazolam (0.003—0.1 mg/kg) and lorazepam (0.001—
0.03 mg/kg) (Sigma-Aldrich, St Louis, MO) were dissolved in
small amounts of 95% ethanol or 100% propylene glycol, and
diluted to desired concentration using propylene glycol (50%)
and water. Cocaine HCl (Sigma-Aldrich, St Louis, MO) was
dissolved in 0.9% saline solution. MRK-696, 7-Cyclobutyl-6(2-methyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)1,2,4-triazolo(4,3-b)pyridazine (0.001—0.03 mg/kg) was prepared in 100% propylene glycol and diluted using 50–80%
propylene glycol and water solutions. MRK-623, 2-(3-(4fluoro-3-pyridin-3-yl-phenyl)-imidazo(1,2-a)pyrimidin-7-yl)propan-2-ol (0.03—3.0 mg/kg); TPA023B, 6,20 -difluoro-50 (3-(1-hydroxy-1-methylethyl)imidazo(1,2-b((1,2,4)triazin-7-yl)
(1,10 -biphenyl)-2-carbonitrile (0.003—0.3 mg/kg); and TP003,
4,20 -difluoro-50 -(8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo
(1,2-a)pyridine-3-yl)biphenyl-2-carbonitrile (0.1—1.8 mg/kg)
were synthesized at the Merck, Sharp & Dohme Neuroscience
Research Centre (Terlings Park, Harlow, UK) as summarized
by (Atack 2011). MRK-623, TPA023B, and TP003 were
prepared in solutions of 10% benzoyl ethanol, 50% propylene
glycol, and 40% water.

Data Analysis
The number of injections/session and the last response
requirement completed in a session (break point, BP) were
determined for individual monkeys for each test drug/dose.
The injections/session data were analyzed by repeated
measures analysis of variance (ANOVA) with dose
as the factor. A dose of drug was determined to be selfadministered significantly above vehicle levels by comparing mean injections/session for each dose to the
corresponding vehicle control value (Bonferroni t-test,
alpha level equal to Po0.05).
The maximum BP (BPmax) was calculated as the highest
BP, irrespective of dose, for each test drug. The BPmax
measure provides an index of reinforcing strength that takes

into account individual differences in peak BP values.
Medians rather than means were used for this analysis
because BP values characteristically violate the assumption
of homogeneity of variance for parametric tests (Rowlett
et al, 1996, 2002). The BPmax data were analyzed with the
nonparametric Friedman’s repeated measures ANOVA on
ranks. Multiple comparisons of BPmax medians to those
for midazolam were conducted using Dunnett’s tests for
ranks (Po0.05).
The doses of compound needed to engender 50% of
the maximum effect (ED50) were calculated based on the
number of injections/session data, only after significant selfadministration was obtained (ie, at least one dose of compound
engendered an average number of injections/session that was
significantly different from vehicle). The ED50 values were
determined by non-linear regression analysis. An iterative
curve-fitting procedure for sigmoidal dose-response functions
with variable slopes was used (Rowlett, 2000). The equation
used was the four-parameter logistic equation: Y ¼ min þ
max  (max/(1 þ eslope/dose—ED50)), where min equals the number of injections/session obtained with vehicle availability
and max equals the highest values obtained with compound.
All parameters in the nonlinear regression analysis were free
to vary.

RESULTS
Self-Administration of Midazolam and Lorazepam
Under midazolam baseline conditions, the 0.03 mg/kg/
injection dose of midazolam maintained an average of
15 injections/session (SEM ¼ 1.0) whereas saline availability
resulted in an average of 3.5 injections/session (SEM ¼ 0.57;
data not shown). Under cocaine baseline conditions, the
0.03 mg/kg/injection dose of cocaine maintained an average
of 17 injections/session (SEM ¼ 1.7) whereas saline availability resulted in an average of 3.0 injections/session
(SEM ¼ 1.0; data not shown). Note there were no differences
between the two baseline conditions when comparing the
mean numbers of injections/session after baseline drug
(midazolam vs cocaine), or between the groups in terms
of mean numbers of injections/session following vehicle
availability (t-tests, P40.05). No substantial changes in
baseline responding occurred for either drug during the
B1.5 year duration of this study.
As anticipated, both midazolam and lorazepam were
self-administered reliably above vehicle levels when the
number of injections/session was analyzed (Figure 2). Doses
of midazolam at 0.03 and 0.1 mg/kg/injection were selfadministered significantly above vehicle levels under both
midazolam- and cocaine-baseline conditions (Figure 2a.,
Bonferroni t-tests, Po0.05 vs vehicle). When the conventional benzodiazepine agonist lorazepam was made available to these monkeys, significant self-administration was
observed under both baseline conditions (Figure 2b).
When 0.001  0.03 mg/kg/injection of lorazepam was made
available to monkeys under midazolam baseline conditions,
the mean number of injections/session of the two highest
doses (0.01 and 0.03 mg/kg/injection) but not the two lower
doses were significantly above vehicle levels (Figure 2b,
Bonferroni t-tests, Po0.05 vs vehicle). Similarly, under
cocaine baseline conditions, lorazepam maintained mean
Neuropsychopharmacology
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not maintain self-administration under the cocaine baseline, even when a higher dose (0.3 mg/kg/injection) was
tested (Figure 3b, Bonferroni t-tests, P40.05 vs vehicle).
A similar profile of effects was observed for MRK-623,
which has functional selectivity for a2GABAA and a3GABAA
receptors. MRK-623 maintained a mean number of injections/session above vehicle levels at doses of 0.1 and 0.3 mg/
kg/injection in the midazolam baseline group (Figure 3c,
Bonferroni t-tests, Po0.05 vs vehicle). Under cocaine
baseline conditions, however, MRK-623 did not maintain
average injections/session above vehicle levels at any dose,
even when the dose was increased above the maximum
tested under midazolam conditions (Figure 3c, Bonferroni
t-tests, P40.05 vs vehicle).
Finally, the most selective of the compounds tested,
TP003 (functional selectivity for a3GABAA receptors),
maintained a mean number of injections/session above
vehicle levels at doses of 1.0 and 1.8 mg/kg/injection under
the midazolam baseline (Figure 3d, Bonferroni t-tests,
Po0.05 vs vehicle). As with TPA023B and MRK-623,
TP003 did not maintain a mean number of injections/
session above vehicle levels at any dose tested under cocaine
baseline conditions (Figure 3d, Bonferroni t-tests, P40.05
vs vehicle). Note that doses higher than 1.8 mg/kg/injection
of TP003 were not evaluated due to solubility limits.
Figure 2 Self-administration of conventional benzodiazepine agonists
under a progressive-ratio schedule of i.v. midazolam or cocaine injection.
(a) Intravenous self-administration of midazolam by rhesus monkeys trained
to press a lever to obtain injections of 0.03 mg/kg/injection of midazolam
(N ¼ 4; filled symbols, ‘midazolam baseline’) or 0.03 mg/kg/injection of
cocaine (N ¼ 4; open symbols, ‘cocaine baseline’). Data are mean (± SEM)
injections per session, out of a total of 20 injections available in a daily
session. Points above ‘V’: vehicle tests. Note that *Po0.05 vs vehicle
(Bonferroni t-tests). (b) Self-administration of lorazepam under the same
conditions as described for panel a.

number of injections/session above vehicle levels for 0.01
and 0.03 mg/kg/injection (Figure 2b, Bonferroni t-tests,
Po0.05 vs vehicle).

Comparison of Potencies
Potencies based on the number of injections/session could
be calculated for MRK-696, TPA023B, MRK-623, and TP003
under midazolam baseline conditions, although note that
the extent to which the dose-response functions for both
MRK-623 and TP003 are ‘asymptotic’, ie, reach a maximum
level for several doses, is unclear. Nevertheless, all nonlinear regression analyses resulted in relatively high
correlation coefficients (R2 ¼ 0.71—0.93). The ED50 values
(±SEM) are shown in Table 1, and reveal a rank order
of potency of MRK-6964TPA023B4MRK-6234TP003.

Comparison of Relative Reinforcing Strength
MRK-696 and Functionally-Selective Compounds
After establishment of self-administration of the conventional benzodiazepines midazolam and lorazepam under
both baseline conditions, we evaluated the four novel
compounds for self-administration. As with the nonselective conventional benzodiazepines, the non-selective
partial agonist MRK-696 maintained a mean number of
injections/session above vehicle levels at doses of 0.003–
0.03 mg/kg/injection under both midazolam and cocaine
conditions (Figure 3a, Bonferroni t-tests, Po0.5 vs vehicle).
For the compounds lacking efficacy at a1GABAA receptors but with functional selectivity for different GABAA
receptor subtypes, a different pattern of effects was
observed. In this regard, TPA023B, a compound lacking
significant efficacy at a1GABAA receptors but with functional selectivity for a2GABAA, a3GABAA and a5GABAA
receptors, maintained a mean number of injections above
vehicle levels for doses of 0.01, 0.03, and 0.1 mg/kg/injection
under the midazolam baseline (Figure 3b, Bonferroni
t-tests, Po0.05 vs vehicle). However, this compound did
Neuropsychopharmacology

Evaluation of BPmax values (ie, maximum break point, BP,
irrespective of dose) showed median values for midazolam
and lorazepam of 240  320 responses/injection under both
midazolam and cocaine baseline conditions (Figure 4).
Under the midazolam baseline condition, comparisons
with lorazepam and the four novel compounds revealed
significant effects (repeated measures Friedman’s ANOVA)
that were due to BPmax values for MRK-696, TPA023B,
MRK-623, and TP003; but not lorazepam, being lower than
the BPmax values obtained with midazolam (Figure 4a,
Dunnett’s tests, Po0.05).
Under the cocaine baseline, median BPmax values for
TPA023B, MRK-623, and TP003 were not calculated due to
the lack of statistical significance between vehicle and any
dose of the three compounds (see above). Thus, median
BPmax values were calculated for midazolam, lorazepam,
and MRK-696 only, and when the values for lorazepam
and MRK-696 were compared with those of midazolam,
only MRK-696 maintained a lower median BPmax value
(Figure 4b, Dunnett’s tests, Po0.05).

Reinforcing Effects, Benzodiazepines, and Subtypes
NM Shinday et al

1011

Figure 3 Differential self-administration of compounds with varying degrees of efficacy GABAA receptor subtypes. (a) Intravenous self-administration of
MRK-696 (no differences in efficacy across subtypes) in rhesus monkeys trained under a progressive-ratio schedule of midazolam (0.03 mg/kg/injection;
N ¼ 4, ‘midazolam baseline’) or cocaine (0.03 mg/kg/injection, N ¼ 4; ‘cocaine baseline’). Data are mean (± SEM) injections per session, out of a total of 20
injections available in a daily session. Points above ‘V’: vehicle tests. Note that *Po0.05 vs vehicle (Bonferroni t-tests). (b) Self-administration of TPA023B
(near zero efficacy at a1 subunit-containing receptors, ie, ‘a1-sparing’; partial agonist at a2, a3, and a5 subunit-containing receptors) under the same
conditions as described for panel a. (c) Self-administration of MRK-623 (near zero efficacy at a1 subunit-containing receptors, ie, ‘a1-sparing’; highest efficacy
at a2, a3 subunit-containing receptors) under the same conditions as described for panel a. (d) Self-administration of TP003 (zero efficacy at a1 subunitcontaining receptors, ie, ‘a1-sparing’; highest efficacy at a3 subunit-containing receptors; near zero efficacy at a2 and a5 subunit-containing receptors) under
the same conditions as described for panel a. See Figure 1 for receptor subtype selectivity profiles.

DISCUSSION
Expanding on our previous findings with the a1-sparing
compound L-838,417 (Rowlett et al, 2005), we show that
a1-sparing compounds with varying pharmacodynamic and
pharmacokinetic profiles can have reinforcing effects in
rhesus monkeys. However, self-administration of a1-sparing compounds appears to depend critically on baseline
conditions, as all compounds tested had reinforcing effects
in monkeys experienced primarily with midazolam, but not
in monkeys experienced primarily with cocaine. Under
cocaine baseline conditions, our findings are consistent
with the prediction advanced by Tan et al (2010) that
a1-sparing compounds should be without reinforcing
effects, possibly due to a lack of disinhibition of VTA
dopaminergic neurons that innervate the NAc. In contrast,
our findings that a1-sparing compounds have reinforcing
effects under the midazolam baseline condition is more
consistent with recent results reported by Reynolds et al
(2012), in which the a1GABAA receptor appeared to have
little role in benzodiazepine-induced enhancement of
reward thresholds in an intra-cranial self-stimulation
procedure.
In our studies, the a1-sparing compounds had lower
relative reinforcing strength (as determined by the BPmax)
than conventional benzodiazepines such as midazolam and
lorazepam. These findings collectively suggest that a1sparing compounds may have reduced abuse liability
compared with non-selective benzodiazepines. Conversely,

drugs that bind preferentially to a1GABAA receptors have a
higher degree of relative reinforcing strength than conventional benzodiazepines and a1-sparing compounds
(eg, Ator, 2002; Rowlett et al, 2005). On the basis of these
findings, we speculated previously that the a1GABAA
subtype might have a facilitative role in the reinforcing
effects of benzodiazepines (Rowlett et al, 2005; Licata and
Rowlett, 2011). One prediction from this idea is that a nonselective partial agonist would have a higher degree of
relative reinforcing strength relative to a1-sparing compounds that are partial agonists at the other GABAA
receptors. This prediction is based, in part, on the finding
by Licata and Rowlett (2011) that the non-selective partial
agonist, bretazenil, had reinforcing strength similar to that
of midazolam. However, in the present study, a direct
comparison of the non-selective partial agonist MRK-696
with the a1-sparing compounds revealed no differences in
relative reinforcing strength; thus providing little support
for the idea of a facilitative role for the a1GABAA receptor
subtype.
As described above, recent work has implicated a1
subunit-containing GABAA receptors on GABAergic interneurons in the VTA as key mediators of the reinforcing
effects of benzodiazepines (Heikkinen et al, 2009; Tan et al,
2010, 2011). In this regard, benzodiazepines would increase
inhibition of these neurons, thus relieving their tonic
inhibition of DA neurons (Tan et al, 2010, 2011), and
resulting in the hallmark DA increase observed with other
Neuropsychopharmacology
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Figure 4 Relative reinforcing effectiveness of benzodiazepine agonists
and novel compounds under progressive-ratio schedules of midazolam (a)
or cocaine (b) injection. Data are derived from break points, ie, the highest
response requirement completed in a session, and expressed in terms of
BPmax, which is the highest break point obtained irrespective of dose. Data
are median (± interquartile range) due to lack of homogeneity of variance
associated with break point data sets (see text for details). Note that
*Po0.05 vs median BPmax for midazolam, Dunnett’s test for ranks.
Also note that # indicates that self-administration was not significantly
different from vehicle for any dose which did not allow determination of
break point values.

drugs of abuse (Lüscher and Ungless, 2006). Although these
findings assume that increased DA in the NAc is the
mechanism for benzodiazepine self-administration, there is
no direct evidence to date documenting such an increase.
In fact, there is evidence suggesting that benzodiazepines
may actually decrease DA release (eg, Lavielle et al, 1979;
Finlay et al, 1992; Harada et al, 1992; Murai et al, 1994).
Moreover, in healthy drug-inexperienced people, benzodiazepine-type drugs and drugs that bind preferentially to a1
subunit-containing receptors (eg, zolpidem) are characteristically found to be unpleasant and/or aversive (Licata and
Rowlett, 2008; Licata et al, 2008).
Although no unifying hypothesis of the reinforcing/
rewarding effects of benzodiazepine-type drugs is evident
at this time, our findings with different training baselines
may help to reconcile some aspects of the differing results
across species and procedures. Notably, the suggestion by
(Tan et al, 2010, 2011) that a1-sparing compounds should
lack or have reduced reinforcing effects is supported by
our findings, but only with cocaine-experienced monkeys.
Moreover, this observation is generally consistent with an
earlier report that the conventional benzodiazepine agonist
diazepam was not self-administered by a majority of
monkeys trained to self-administer cocaine, but was selfadministered by all monkeys trained with the barbiturate
GABAergic modulator, pentobarbital (Bergman and
Johanson, 1985). One potential implication of these findings
Neuropsychopharmacology

is that exposure to GABAergic positive modulators vs
cocaine exposure results in different neuroplastic outcomes,
such that increases in DA neurotransmission in the
mesolimbic system are critical for reinforcing effects of
benzodiazepines after cocaine exposure, but not midazolam
(or pentobarbital) exposure. That is, the hypothesis of
(Tan et al, 2010, 2011) that a1GABAA receptors mediate the
addictive effects of benzodiazepines applies to cocaineexposed, but not midazolam-exposed subjects.
In addition to differences in neuroplasticity, there are
other possible explanations for the divergence in selfadministration of a1-sparing compounds for midazolam- vs
cocaine-experienced monkeys to consider. For example,
self-administration of a1-sparing compounds might depend
on the extent to which compounds share discriminative
stimulus effects with the two training drugs. Cocaine
characteristically does not share discriminative stimulus
effects with benzodiazepines (eg, Negus et al, 2000).
However, in the present study, midazolam and lorazepam,
as well as the non-selective partial agonist MRK-696,
were self-administered under the cocaine baseline condition
in a manner similar to the midazolam baseline condition,
both in terms of potency and relative reinforcing strength.
Conversely, we have shown previously that the a1-sparing
compound L-838,417 was self-administered under a methohexital baseline, yet did not share discriminative stimulus
effects with the non-selective BZ, triazolam (Rowlett et al,
2005). These findings suggest that the differences in selfadministration between midazolam vs cocaine baseline
conditions were not simply a matter of benzodiazepine-like
vs cocaine-like discriminative stimulus effects. These results
are in line with previous studies, which have demonstrated
that animals will self-administer drugs that do not share
discriminative stimuli with the training drug (Ator, 2002).
Another possibility is that a1-sparing compounds possess
effects that suppress, or impair, lever pressing; and these
effects are attenuated in midazolam- but not cocaineexperienced monkeys. However, a1-sparing compounds
generally lack sedative-motor effects in monkeys and do
not impair performance in tasks requiring lever pressing
(Rowlett et al, 2005; Fischer et al, 2010, 2011).
Although our findings are not consistent with the idea
that a1-sparing compounds lack abuse potential entirely, we
have evidence for a GABAA receptor subtype that is perhaps
critical for mediating the reinforcing effects of benzodiazepines, at least under midazolam baseline conditions. In this
regard, TP003, a compound with functional selectivity for
the a3GABAA receptor (Dias et al, 2005), had reinforcing
effects in the benzodiazepine-experienced monkeys. Interestingly, selective activation of the a3GABAA receptor would
be predicted to decrease DA release in the NAc (Tan et al,
2011). If borne out, the combination of TP003 selfadministration with decreased DA release in the NAc would
provide a clear exception to current hypotheses regarding
the neurobiological mechanisms of reinforcement.
Although provocative, the results with TP003 must be
approached with some caution. In particular, the rank order
of potencies of the a1-sparing compounds did not match
the rank order of potencies for binding affinities for
any of the GABAA receptor subtypes. This mismatch was
due primarily to TP003 having relatively high potency
in vitro, but the lowest potency of all the compounds in
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self-administration. This raises the possibility of TP003
acting at a non-GABAA site, although there is no evidence to
date for this compound having activity at other receptor
systems (Dias et al, 2005). One possible explanation for this
relative lack of in vivo potency for TP003 is that this
compound consistently requires a high degree of binding
site occupancy to engender behavioral effects, in contrast to
most benzodiazepine-type compounds (Dias et al, 2005).
Nevertheless, it is unknown at present what degree of
binding site occupancy is required for behavioral effects in
rhesus monkeys and, in fact, the pharmacokinetic profile of
TP003 in this species has not yet been established.
Given that drugs that bind preferentially to a1GABAA
receptors (eg, zolpidem) have reinforcing effects, we
propose that intrinsic efficacy at a3GABAA receptors alone
is sufficient for benzodiazepine self-administration under
midazolam baseline conditions. In contrast, intrinsic
efficacy at a1GABAA receptors is necessary for benzodiazepine self-administration under cocaine baseline conditions.
The neurobiological basis for these differential mechanisms
of action remains to be discovered.
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